Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC₅₀ of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC₅₀ of 2.4±0.5 nM (range, 1.5-2.9 nM)^[1]. Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not increase Gαs mRNA levels^[2]. Trichostatin A (20-75?nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs^[3]. In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Trichostatin A (500 μg/kg, s.c.) pronounces antitumor activity without causing any measurable toxicity in doses of up to 5 mg/kg by s.c. injection, in randomized controlled efficacy studies using the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

302.37

Solid

C₁₇H₂₂N₂O₃

58880-19-6

曲古抑菌素A

Room temperature in continental US; may vary elsewhere.